Bringing together a collection of the most forward-thinking approaches to lung disease, the European Respiratory Society (ERS) International Congress 2021 hosted a virtual session on imaging biomarkers. Four insightful presentations discussed the shift towards more longitudinal imaging approaches for lung disease and provided an overview of quantitative analyses with computer-trained algorithms. Alongside this was a discussion of the use of novel biomarkers such as pleuroparenchymal fibroelastosis.

Tracheal stenosis (TS) after long-term artificial lung ventilation remains a problem in the Russian region. In the Urals region during…

Wheeze is difficult to describe and recognise, and there is a need for clear guidelines on diagnosing wheeze. Discrepancy exists between…

Dyspnoea and exercise intolerance are near universal symptoms in fibrotic interstitial lung disease (fILD).1 Neither anti-fibrotic agents…

This symposium took place during the 2021 virtual meeting of the European Respiratory Society (ERS). It focused on improving the…

During the European Respiratory Society (ERS) International Congress 2021, speakers discussed the latest updates to the ERS…

Pneumomediastinum (PM) is a rare pathological entity that is divided into two categories: secondary, with a well-known aetiology, and…

As a medical student in Edinburgh, I was inspired by the opportunities in Edinburgh to combine clinical and basic science research in respiratory medicine.

I have always been incredibly interested in science and in trying to understand how things work. My first degree was in natural sciences at Cambridge, UK, where I specialised in neurobiology, and this exposed me to the beauty and rigor of basic science.

Vaccination is currently the most powerful tool for controlling the COVID-19 pandemic.1 In large randomised controlled trials, the approved vaccines have shown good efficacy and safety.2 However, there is increasing concern about the safety of the adenovirus-based COVID-19 vaccines of AstraZeneca (ChAdOx1 nCoV-19) and Janssen (Ad26.COV2.S).